首页> 外文OA文献 >Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity
【2h】

Exoplasmic cysteine Cys384 of the HDL receptor SR-BI is critical for its sensitivity to a small-molecule inhibitor and normal lipid transport activity

机译:HDL受体SR-BI的胞外半胱氨酸Cys384对于其对小分子抑制剂的敏感性和正常的脂质转运活性至关重要

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The HDL receptor, scavenger receptor, class B, type I (SR-BI), is a homooligomeric cell surface glycoprotein that controls HDL structure and metabolism by mediating the cellular selective uptake of lipids, mainly cholesteryl esters, from HDL. The mechanism underlying SR-BI-mediated lipid transfer, which differs from classic receptor-mediated endocytosis, involves a two-step process (binding followed by lipid transport) that is poorly understood. Our previous structure/activity analysis of the small-molecule inhibitor blocker of lipid transport 1 (BLT-1), which potently (IC50 ∼ 50 nM) blocks SR-BI-mediated lipid transport, established that the sulfur in BLT-1’s thiosemicarbazone moiety was essential for activity. Here we show that BLT-1 is an irreversible inhibitor of SR-BI, raising the possibility that cysteine(s) in SR-BI interact with BLT-1. Mass spectrometric analysis of purified SR-BI showed two of its six exoplasmic cysteines have free thiol groups (Cys251 and Cys384). Converting Cys384 (but not Cys251) to serine resulted in complete BLT-1 insensitivity, establishing that the unique molecular target of BLT-1 inhibition of cellular SR-BI dependent lipid transport is SR-BI itself. The C384S substitution reduced the receptor’s intrinsic lipid uptake activity by approximately 60% without dramatically altering its surface expression, homooligomerization, or HDL binding. Thus, a small-molecule screening approach identified a key residue in SR-BI involved in lipid transport, providing a powerful springboard into the analyses of the structure and mechanism of SR-BI, and highlighting the power of this approach for such analyses.
机译:HDL受体,清除剂受体,B类,I型(SR-BI),是一种低聚细胞表面糖蛋白,可通过介导从HDL选择性吸收脂质(主要是胆固醇酯)来控制HDL结构和代谢。与经典的受体介导的内吞作用不同,SR-BI介导的脂质转移的潜在机制涉及一个两步过程(结合后进行脂质转运),这一过程目前尚不清楚。我们先前对脂质转运1(BLT-1)的小分子抑制剂阻滞剂(其有效(IC50〜50 nM)阻断SR-BI介导的脂质转运)的结构/活性分析确定,BLT-1的硫半碳环素部分中的硫对于活动至关重要。在这里,我们显示BLT-1是SR-BI的不可逆抑制剂,从而增加了SR-BI中的半胱氨酸与BLT-1相互作用的可能性。纯化SR-BI的质谱分析显示,其六个胞质半胱氨酸中有两个具有游离巯基(Cys251和Cys384)。将Cys384(而不是Cys251)转化为丝氨酸会导致BLT-1完全不敏感,从而确定BLT-1抑制细胞SR-BI依赖性脂质转运的唯一分子靶点是SR-BI本身。 C384S取代将受体的固有脂质吸收活性降低了约60%,而没有显着改变其表面表达,均聚或HDL结合。因此,一种小分子筛选方法确定了SR-BI中参与脂质转运的关键残基,为分析SR-BI的结构和机理提供了有力的跳板,并突出了这种方法在此类分析中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号